Aquestive CEO exercises warrant for 91,743 shares
Rhea-AI Filing Summary
Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber exercised a Common Stock Purchase Warrant for 91,743 shares of common stock on September 8, 2026 at an exercise price of $0.96 per share for cash, increasing his direct common stock holdings to 677,317 shares and exhausting the warrant.
Positive
- None.
Negative
- None.
Insider Trade Summary
91,743 shares exercised/converted
Exercise
2 txns
Insider
Barber Daniel
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Warrant (Right to Buy) | 91,743 | $0.00 | $0.00 |
| In-the-Money Exercise | Common Stock F1 | 91,743 | $0.96 | $88K |
Holdings After Transaction:
Warrant (Right to Buy) — 0 contracts (Direct);
Common Stock — 677,317 shares (Direct)
Footnotes (1)
- F1. Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.
Key Figures
Common shares acquired via warrant exercise: 91,743 shares
Exercise price: $0.96 per share
Direct common stock holdings after transaction: 677,317 shares
+3 more
6 metrics
Common shares acquired via warrant exercise
91,743 shares
Exercised on September 8, 2026 by the President and CEO
Exercise price
$0.96 per share
Cash exercise of Common Stock Purchase Warrant for 91,743 shares
Direct common stock holdings after transaction
677,317 shares
Direct ownership by Daniel Barber following the September 8, 2026 exercise
Warrant shares exercised (derivative leg)
91,743 warrants
Warrant (Right to Buy) exercised and reduced to zero following transaction
Warrant exercisability date
December 8, 2022
Date the Common Stock Purchase Warrant became exercisable
Warrant expiration date
June 8, 2027
Scheduled expiration of the Common Stock Purchase Warrant
Key Terms
Common Stock Purchase Warrant, Securities Purchase Agreement, exercise price
3 terms
Common Stock Purchase Warrant financial
"Represents the exercise for cash of a Common Stock Purchase Warrant issued"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Securities Purchase Agreement financial
"issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
exercise price financial
"and has an exercise price of $0.96 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What insider transaction did AQST report for CEO Daniel Barber?
Aquestive Therapeutics reported that CEO Daniel Barber exercised a warrant to acquire 91,743 shares of common stock on September 8, 2026 at an exercise price of $0.96 per share, increasing his direct holdings to 677,317 shares.
What were the terms of the AQST warrant exercised by the CEO?
The exercised Common Stock Purchase Warrant covered 91,743 shares, had an exercise price of $0.96 per share, became exercisable on December 8, 2022, and was scheduled to expire on June 8, 2027, according to the footnote description.
Was the AQST CEO’s warrant exercise under a Rule 10b5-1 trading plan?
No. The filing indicates that the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the September 8, 2026 warrant exercise for 91,743 shares was executed pursuant to a Rule 10b5-1 trading plan.
Did the AQST CEO pay cash to exercise the warrant?
Yes. A footnote states that the transaction represents the exercise for cash of a Common Stock Purchase Warrant for 91,743 shares at an exercise price of $0.96 per share, issued under a Securities Purchase Agreement dated June 6, 2022.
AI-generated analysis. How Rhea-AI works. Not financial advice.
